Artal Group S.A. Kymera Therapeutics, Inc. Transaction History

Artal Group S.A.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$29.85 - $39.42 $642,521 - $848,515	-21,525 Reduced 0.71%	3,005,610 $89.7 Million
Q1 2024 May 13, 2024	BUY	$22.9 - $43.57 $11.4 Million - $21.6 Million	496,400 Added 19.61%	3,027,135 $122 Million
Q4 2023 Feb 09, 2024	BUY	$10.97 - $26.84 $7.96 Million - $19.5 Million	725,389 Added 40.18%	2,530,735 $64.4 Million
Q1 2023 May 12, 2023	SELL	$24.84 - $38.75 $4.84 Million - $7.54 Million	-194,654 Reduced 9.73%	1,805,346 $53.5 Million
Q4 2022 Feb 13, 2023	BUY	$19.57 - $30.92 $9.79 Million - $15.5 Million	500,000 Added 33.33%	2,000,000 $49.9 Million
Q3 2022 Nov 14, 2022	BUY	$20.91 - $34.27 $10.5 Million - $17.1 Million	500,000 Added 50.0%	1,500,000 $32.7 Million
Q4 2021 Feb 11, 2022	BUY	$49.91 - $65.56 $29.9 Million - $39.3 Million	600,000 Added 150.0%	1,000,000 $63.5 Million
Q3 2021 Nov 12, 2021	BUY	$47.8 - $66.66 $7.17 Million - $10 Million	150,000 Added 60.0%	400,000 $23.5 Million
Q3 2020 Nov 13, 2020	BUY	$26.1 - $33.28 $6.53 Million - $8.32 Million	250,000 New	250,000 $8.08 Million

183

64.3M

50.6K

81.7K

Ticker KYMR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,705,800
Market Cap $2.43B
Description
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.